
Opinion|Videos|October 4, 2024
Impact of Transplant Eligibility on Treatment Selection
Panelists discuss how transplant eligibility significantly influences first-line treatment goals and initial therapy selection in multiple myeloma, often leading to more intensive induction regimens aimed at achieving deep remissions.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How does transplant eligibility impact first-line treatment goals and selection of initial therapy?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
US Measles Cases Climb, Raising Questions About Preparedness and Prevention
2
FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma
3
Afamitresgene autoleucel: The First T-Cell Receptor Therapy on the Market
4
The Return of Belantamab Mafodotin: Past Lessons, Present Promise, and Future Impact
5















































































































































































































